Efficacy and Safety of L Arginine to Prevent Preeclampsia
NCT ID: NCT02363348
Last Updated: 2016-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
96 participants
INTERVENTIONAL
2010-08-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
applied to pregnant women with risk factors for preeclampsia. the main result was the development of preeclampsia as well as side effects to taking l arginine besides perinatal outcomes
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-Arginine in Pre-Eclampsia
NCT00157521
L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia
NCT00469846
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
NCT05934318
Role of L-citrulline in Prevention of Pregnancy Associated Hypertension
NCT04979793
L-arginine Effects on Chronic Hypertension in Pregnancy
NCT00974714
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each three weeks were evaluated in search of high blood pressure and proteinuria.
The follow-up was until the end of pregnancy and two weeks after this
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo (A)
were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.
dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
Placebo
calcined magnesia
L arginine (B)
were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
L arginine
L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L arginine
L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
Placebo
calcined magnesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pre gestational diabetes
* multiple pregnancy and were removed for some reason they received medication that would interfere with the interpretation of results (aspirin)
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Civil Juan I. Menchaca
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eva Elizabet Camarena Pulido
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guadalupe Panduro, Ph
Role: STUDY_CHAIR
Hospital Civil Juan I. Menchaca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Panduro Baron J Guadalupe
Guadalajara, Jalisco, Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Johal T, Lees CC, Everett TR, Wilkinson IB. The nitric oxide pathway and possible therapeutic options in pre-eclampsia. Br J Clin Pharmacol. 2014 Aug;78(2):244-57. doi: 10.1111/bcp.12301.
Vadillo-Ortega F, Perichart-Perera O, Espino S, Avila-Vergara MA, Ibarra I, Ahued R, Godines M, Parry S, Macones G, Strauss JF. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ. 2011 May 19;342:d2901. doi: 10.1136/bmj.d2901.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSJ1054-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.